Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of Tocilizumab for TAO
NCT06087731 · Sun Yat-sen University · PHASE2 · withdrawn · last registry update 2023-11-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “For some personal reasons.” | – | Registry record, Sun Yat-sen University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL6R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-11-01Also stopped (terminated): University of Zurich, Actemra (NCT04652258)
- 2024-10-23Phase 3 first posted: Duke University, TNFi (Tumor Necrosis Factor inhibitor) medication + Abatacept (NCT06654882)
- 2024-10-15Results posted on the registry: Sanofi, Sarilumab (NCT02776735)
- 2024-10-09Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), lulizumab pegol + antithymocyte globulin (rabbit) (NCT04066114)
- 2024-10-09Results posted on the registry: NYU Langone Health, Ipilimumab + Nivolumab (NCT03999749)
- 2024-10-08Results posted on the registry: Celltrion, CT-P47 + EU-approved RoActemra (NCT05489224)
- 2024-10-04Results posted on the registry: Hoffmann-La Roche, Mosunetuzumab SC + Tiragolumab (NCT05315713)
- 2024-10-04Also stopped (terminated): Hoffmann-La Roche, Mosunetuzumab SC + Tiragolumab (NCT05315713)
- 2024-09-03Also stopped (withdrawn): Genentech, Inc., RO7617991 + Tocilizumab (NCT06372574)
- 2024-08-23Also stopped (terminated): Hoffmann-La Roche, RO7443904 + Glofitamab (NCT05219513)
- 2024-08-09Also stopped (terminated): Hoffmann-La Roche, Obinutuzumab + Atezolizumab (NCT03866239)
- 2024-07-09Also stopped (terminated): Hoffmann-La Roche, RO7515629 + tocilizumab (NCT05769959)
- 2024-06-26Phase 3 first posted: AO GENERIUM, Complarate® + Actemra® (NCT06475508)
- 2024-06-11Phase 3 first posted: Tianjin Medical University General Hospital, Tocilizumab + Prednisone (NCT06452537)
- 2024-06-07Phase 3 first posted: Zhujiang Hospital, Tocilizumab + NaCl 0.9% 100ml (NCT06447701)
- 2024-06-04Also stopped (terminated): Columbia University, Itacitinib + Tocilizumab (NCT04070781)
- 2024-03-25Results posted on the registry: Hoffmann-La Roche, Glofitamab + Gemcitabine (NCT04313608)
- 2024-03-06Phase 3 first posted: National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland, Tocilizumab + Nintedanib (NCT06297096)
- 2024-02-07Results posted on the registry: GlaxoSmithKline, Otilimab (GSK3196165) + csDMARD(s) (NCT04333147)
- 2024-02-07Also stopped (terminated): GlaxoSmithKline, Otilimab (GSK3196165) + csDMARD(s) (NCT04333147)
- 2024-02-02Phase 3 first posted: Suzhou Municipal Hospital of Anhui Province, Tocilizumab + NaCl 0.9% 100ml (NCT06238024)
- 2024-01-17Results posted on the registry: M.D. Anderson Cancer Center, Alemtuzumab + Etoposide (NCT02385110)
- 2023-12-11Results posted on the registry: Hoffmann-La Roche, Tocilizumab (NCT01664598)
- 2023-10-30Phase 3 first posted: Hoffmann-La Roche, Satralizumab + Placebo (NCT06106828)
- 2023-10-23Results posted on the registry: Weill Medical College of Cornell University, Tocilizumab + Fludarabine (NCT04395222)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision